Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma

Molecular Medicine
YanGuo KongJoseph M Tuscano

Abstract

Checkpoint kinase inhibition has been studied as a way of enhancing the effectiveness of DNA-damaging agents. More recently, histone deacetylase inhibitors have shown efficacy in several cancers, including non-Hodgkin lymphoma. To evaluate the effectiveness of this combination for the treatment of lymphoma, we examined the combination of AR42, a histone deacetylase inhibitor, and checkpoint kinase 2 (CHEK2) inhibitor II in vitro and in vivo. The combination resulted in up to 10-fold increase in potency in five Burkitt lymphoma cell lines when compared with either drug alone. Both drugs inhibited tumor progression in xenograft models, but the combination was more effective than either agent alone, resulting in regression of established tumors. No toxicity was observed. These results suggest that the combination of histone deacetylase inhibition and checkpoint kinase inhibition represent an effective and nontoxic treatment option that should be further explored in preclinical and clinical studies.

References

Feb 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·M A Cifone, I J Fidler
Jan 1, 1995·Bulletin du cancer·P Biron, J P Droz
Jan 1, 1995·Cancer·T C GreinerE S Jaffe
Jan 7, 2006·Nature Reviews. Cancer·Saverio Minucci, Pier Giuseppe Pelicci
May 6, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yves PommierKurt W Kohn
Sep 5, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Samuel K KulpChing-Shih Chen
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Mar 23, 2007·Applied Microbiology and Biotechnology·Christian HildmannAndreas Schwienhorst
Jul 27, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Yen-Shen LuChing-Shih Chen
Jan 31, 2008·British Journal of Cancer·N Bucher, C D Britten
Jul 23, 2008·Molecular and Cellular Biology·Christine M LovlyHelen Piwnica-Worms
Sep 18, 2008·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Rosario PeronaIsabel Sánchez Pérez
Jan 14, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yun Dai, Steven Grant
Nov 23, 2010·Trends in Molecular Medicine·Cynthia X MaHelen Piwnica-Worms
Apr 5, 2011·Trends in Pharmacological Sciences·Michelle D Garrett, Ian Collins
Jul 21, 2011·Nature Communications·Bojie DaiRonald B Gartenhaus
Dec 14, 2011·Molecular and Cellular Biochemistry·Hee Jung YunHyun Ju Kwon
Jul 28, 2012·Lancet·Kate R ShanklandBarry W Hancock

❮ Previous
Next ❯

Citations

Sep 14, 2021·Frontiers in Veterinary Science·Joana N R DiasFrederico Aires-da-Silva

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.